Biotech company Savara in Phase 3 trials for rare lung disorder drug with Orphan Drug status.
Savara, Inc. is a clinical-stage biotech company developing molgramostim for a rare lung disorder, aPAP, currently in Phase 3 trials. It has Orphan Drug status and significant growth potential. The article highlights a trend favoring small-cap and penny stocks, including Applied Digital Corporation, Ironwood Pharmaceuticals, Autolus Therapeutics, and Indie Semiconductor, all viewed as potential multibaggers for 2025, appealing to risk-tolerant investors.
September 01, 2024
7 Articles